Theravance Biopharma (TBPH) Long-Term Investments (2014 - 2025)

Theravance Biopharma (TBPH) has reported Long-Term Investments for 12 consecutive years, with $11.1 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Long-Term Investments rose 385.51% year-over-year to $11.1 million; the TTM figure through Dec 2025 stood at $11.1 million (up 385.51% YoY), while the FY2025 annual figure was $11.1 million, up 385.51% from the prior year.
• Long-Term Investments grew to $11.1 million in Q4 2025 per TBPH's latest filing, from $3.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $148.2 million in Q2 2022 and bottomed at $2.3 million in Q4 2024.
• Historically, Long-Term Investments has averaged $37.5 million across 5 years, with a median of $19.1 million in 2021.
• Annual changes were most pronounced in 2021 — Long-Term Investments soared 429.7% — and 2023, when it sank 80.05%.
• Theravance Biopharma's Long-Term Investments stood at $67.5 million in 2021, then surged by 119.51% to $148.2 million in 2022, then tumbled by 87.33% to $18.8 million in 2023, then sank by 87.79% to $2.3 million in 2024, then jumped by 385.51% to $11.1 million in 2025.
• Business Quant data shows TBPH's Long-Term Investments at $11.1 million in Q4 2025, $3.0 million in Q3 2025, and $2.4 million in Q2 2025.